Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13–26 years) enrolled in the VALHIDATE study

HPV vaccination is expected to reduce the incidence of cervical cancer. The greatest and the earliest health gains will be ensured by high vaccine coverage among all susceptible people. The high costs and the risk of a reduced cost/effectiveness ratio in sexually active girls still represent the mai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hum Vaccin Immunother
Hauptverfasser: Orlando, Giovanna, Fasolo, Michela, Mazza, Francesca, Ricci, Elena, Esposito, Susanna, Frati, Elena, Zuccotti, Gian Vincenzo, Cetin, Irene, Gramegna, Maria, Rizzardini, Giuliano, Tanzi, Elisabetta, group, VALHIDATE study
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2014
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4896517/
https://ncbi.nlm.nih.gov/pubmed/24423757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.27682
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge